Indication unknown (ecDNA segregation and inheritance)
BOLDBoundless Bio IncCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for BBI-940 in Indication unknown (ecDNA segregation and inheritance). The expected timing is based on the latest available company guidance and may change.
11/5/25- IND submission & FIH trial in H1 2026. 03/09/26:- IND accepted; KOMODO-1 Ph1 trial in ER+/HER2- and TNBC-LAR breast cancer enrolling; initial PoC data expected H2 2028. 03/17/26:- AACR 2026 poster on oral kinesin degrader BBI-940 scheduled for April 21, 2026. 05/08/26:- KOMODO-1 enrollment ongoing. AACR 2026 preclinical data showed robust anti-tumor activity; PoC readout expected within cash runway.
Verification
Confirm timing and program details against the company announcement or filing.